Skip to main content

SITAGLIPTIN and METFORMIN HYDROCHLORIDE 1000 mg/1 / 50 mg/1 Medicare Part D Coverage

Brand name: JANUMET
Dosage form
TABLET, FILM COATED
Route
ORAL
Drug class
Diabetes — DPP-4 Inhibitors
95%
of Medicare Part D plans
cover SITAGLIPTIN and METFORMIN HYDROCHLORIDE
5,265 of 5,530 plans
3.0
Avg. formulary tier
$0.00
Median 30-day copay
$0.00–$0.00
Copay range

Formulary Tier Distribution

How Medicare Part D plans classify SITAGLIPTIN and METFORMIN HYDROCHLORIDE. Lower tiers = lower copays.

Tier 1 - Preferred Generic 3%
162 plans • avg $0.00/mo
Tier 2 - Generic 1%
39 plans • avg $14.64/mo
Tier 3 - Preferred Brand 94%
4,926 plans • avg $5.20/mo
Tier 4 - Non-Preferred Drug 2%
98 plans • avg $55.00/mo
Tier 5 - Specialty 0%
9 plans • avg $7.78/mo
Tier 6 - Select Care 1%
31 plans • avg $0.00/mo

Find the cheapest plan for SITAGLIPTIN and METFORMIN HYDROCHLORIDE

Enter your ZIP code to compare every plan in your area side-by-side.

Compare Plans for SITAGLIPTIN and METFORMIN HYDROCHLORIDE →

Get SITAGLIPTIN and METFORMIN HYDROCHLORIDE Delivered to Your Door

Compare prices and get discounts from trusted online pharmacies

Amazon Pharmacy Hims & Hers GoodRx

DrugCovered may earn commissions from pharmacy purchases. Prices and availability vary. Always consult your doctor before starting or changing medications.

SITAGLIPTIN and METFORMIN HYDROCHLORIDE Medicare Coverage by State

Coverage rates and average costs vary significantly by state. Click a state to see the specific plans available there.

Alabama 100% Arizona 100% Arkansas 100% California 100% Colorado 100% Connecticut 100% Delaware 100% District of Columbia 100% Florida 100% Georgia 100% Hawaii 100% Idaho 100% Illinois 100% Indiana 100% Iowa 100% Kansas 100% Kentucky 100% Louisiana 100% Maine 100% Maryland 100% Massachusetts 100% Michigan 100% Minnesota 100% Mississippi 100% Missouri 100% Montana 100% Nebraska 100% Nevada 100% New Hampshire 100% New Jersey 100% New Mexico 100% New York 100% North Carolina 100% North Dakota 100% Ohio 100% Oklahoma 100% Oregon 100% Pennsylvania 100% Puerto Rico 100% Rhode Island 100% South Carolina 100% South Dakota 100% Tennessee 100% Texas 100% Utah 100% Vermont 100% Virginia 100% Washington 100% West Virginia 100% Wisconsin 100% Wyoming 100%

Alternative Medications in the Same Drug Class

Other drugs in the Diabetes — DPP-4 Inhibitors that Medicare Part D plans also cover.

sitagliptin Avg Tier 3.0 $44.00/mo 5,529 plans sitagliptin Avg Tier 3.0 $44.00/mo 5,529 plans sitagliptin Avg Tier 3.0 $44.00/mo 5,529 plans SITAGLIPTIN and METFORMIN HYDROCHLORIDE Avg Tier 3.0 $0.00/mo 5,265 plans sitagliptin and metformin hydrochloride Avg Tier 3.0 $0.00/mo 5,265 plans sitagliptin and metformin hydrochloride Avg Tier 3.0 $0.00/mo 5,265 plans sitagliptin and metformin hydrochloride Avg Tier 3.0 $0.00/mo 5,265 plans linagliptin Avg Tier 2.9 $0.00/mo 5,050 plans

Related Versions of SITAGLIPTIN and METFORMIN HYDROCHLORIDE

JANUMET 500 mg/1 / 50 mg/1 Brand JANUMET XR XR 500 mg/1 / 50 mg/1 Brand JANUMET XR XR 1000 mg/1 / 100 mg/1 Brand JANUMET XR XR 1000 mg/1 / 50 mg/1 Brand

Frequently Asked Questions about SITAGLIPTIN and METFORMIN HYDROCHLORIDE

95% of Medicare Part D plans cover SITAGLIPTIN and METFORMIN HYDROCHLORIDE. It is most commonly placed on Tier 3. Coverage varies by plan and geographic area.

The median 30-day copay for SITAGLIPTIN and METFORMIN HYDROCHLORIDE on Medicare Part D is $0.00 at a preferred pharmacy. Costs range from $0.00 to $0.00 depending on the plan.

SITAGLIPTIN and METFORMIN HYDROCHLORIDE is placed on Tier 3 by most Medicare Part D plans. Lower tier numbers generally mean lower copays.

0% of plans require prior authorization for SITAGLIPTIN and METFORMIN HYDROCHLORIDE. Prior authorization means your doctor must confirm the drug is medically necessary before the plan will cover it.

Medicare & Health Management Products

Weekly AM/PM Pill Organizer
Shop on Amazon
Medication Record Keeper
Shop on Amazon
Blood Pressure Monitor
Shop on Amazon
Portable Medication Bag
Shop on Amazon

As an Amazon Associate, DrugCovered may earn from qualifying purchases. Product recommendations are for informational purposes and do not constitute medical advice.

Coverage statistics based on CMS formulary data for plan year 2026. Data updated regularly. Methodology →